Jon Lim, FRCP PhD
@drjonlim.bsky.social
Senior Lecturer & Consultant Medical Oncologist in Advanced #Immunotherapy + #CellTherapy at @manchester.ac.uk & The Christie • RISE Lead & MANIFEST Deputy Lead • ESMO #TranslationalResearch Faculty
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
You’re such an inspiration, Adam! Keep going 🙌.
January 17, 2026 at 1:30 PM
You’re such an inspiration, Adam! Keep going 🙌.
Really grateful to you, Evangelos! Your mentorship, guidance and friendship in the lab made a huge difference, especially early on as a new PhD fellow 🤓.
Looking forward to continuing to work closely together in Manchester! 🙌
@uom-dcs.bsky.social
@mcrcnews.bsky.social
@cruk-mi.bsky.social
Looking forward to continuing to work closely together in Manchester! 🙌
@uom-dcs.bsky.social
@mcrcnews.bsky.social
@cruk-mi.bsky.social
January 15, 2026 at 9:14 AM
Really grateful to you, Evangelos! Your mentorship, guidance and friendship in the lab made a huge difference, especially early on as a new PhD fellow 🤓.
Looking forward to continuing to work closely together in Manchester! 🙌
@uom-dcs.bsky.social
@mcrcnews.bsky.social
@cruk-mi.bsky.social
Looking forward to continuing to work closely together in Manchester! 🙌
@uom-dcs.bsky.social
@mcrcnews.bsky.social
@cruk-mi.bsky.social
...and follow this thread 🧵 for how the story evolved:
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
January 14, 2026 at 4:40 PM
...and follow this thread 🧵 for how the story evolved:
We cover:
• TCR-T, CAR-T, TIL & NK-cell approaches
• Lessons from early clinical studies
• Key biological & practical challenges
• Where the field may be heading next
Will cell therapy work in sarcoma❓
#Sarcoma #CellTherapy #CancerImmunotherapy #TranslationalResearch
• TCR-T, CAR-T, TIL & NK-cell approaches
• Lessons from early clinical studies
• Key biological & practical challenges
• Where the field may be heading next
Will cell therapy work in sarcoma❓
#Sarcoma #CellTherapy #CancerImmunotherapy #TranslationalResearch
January 12, 2026 at 5:28 PM
We cover:
• TCR-T, CAR-T, TIL & NK-cell approaches
• Lessons from early clinical studies
• Key biological & practical challenges
• Where the field may be heading next
Will cell therapy work in sarcoma❓
#Sarcoma #CellTherapy #CancerImmunotherapy #TranslationalResearch
• TCR-T, CAR-T, TIL & NK-cell approaches
• Lessons from early clinical studies
• Key biological & practical challenges
• Where the field may be heading next
Will cell therapy work in sarcoma❓
#Sarcoma #CellTherapy #CancerImmunotherapy #TranslationalResearch
Reposted by Jon Lim, FRCP PhD
Thanks for highlighting our paper in your wonderful News & Views!
January 2, 2026 at 8:17 PM
Thanks for highlighting our paper in your wonderful News & Views!
Reposted by Jon Lim, FRCP PhD
Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
January 4, 2026 at 1:12 PM
Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
Thanks Rupert 🙏.
January 2, 2026 at 8:58 PM
Thanks Rupert 🙏.